← Back to Search

Behavioural Intervention

Visual Retraining for Stroke-Related Vision Loss (urochester Trial)

N/A

Waitlist Available

Research Sponsored by University of Rochester

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Between 21 and 75 years of age

Able to fixate on visual targets reliably for 1000ms

Must not have

Past or present eye disease interfering with visual acuity

Damage to the dorsal Lateral Geniculate Nucleus

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 8-12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is studying the effects of visual cortex damage and how intensive visual retraining can help reverse it. It will improve understanding of visual system damage & recovery.

Who is the study for?

This trial is for U.S. or Canadian residents aged 21-75 who've had a stroke causing visual field defects, can focus on visual targets, and have normal cognitive abilities to follow instructions in English. Excluded are those with eye diseases affecting vision, certain brain damages, drug/alcohol abuse history, neuroactive medication use impacting training, cognitive/seizure disorders, attentional neglect or inability to perform exercises.

What is being tested?

The study tests the impact of intensive visual retraining on people with vision loss due to stroke-related damage to the primary visual cortex. It aims to understand how this training might improve perception and spatial awareness by assessing changes in brain function and real-world application.

What are the potential side effects?

Since this trial involves non-invasive visual retraining exercises rather than medication or surgery, traditional side effects are not expected. However, participants may experience fatigue or frustration during the training process.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 21 and 75 years old.

Select...

I can focus on visual targets for at least 1 second.

Select...

I had a stroke affecting my vision between ages 21-75.

Select...

I have no history of neurological disorders.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have an eye condition that affects my vision.

Select...

I have damage to a specific part of my brain related to vision.

Select...

My brain is affected by a widespread degenerative condition.

Select...

I have a cognitive or seizure disorder.

Select...

I have damage to my vision system.

Select...

I have an active disease affecting my nervous system.

Select...

I have lost some of my vision due to an eye condition.

Select...

I am unable to do the visual training exercises as required.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 8-12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 8-12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 8-12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in Mean Contrast Sensitivity for Direction

Change in Mean Contrast Sensitivity for Static Orientation

Change in Mean Direction Discrimination Threshold

+1 more

Secondary study objectives

Goldmann perimetry

Humphrey 10-2 and 24-2 perimetry

MAIA Visual Field Perimetry

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Experimental: Cortically Blind (CB) SubjectsExperimental Treatment1 Intervention

Cortically Blind subjects will be enrolled to perform a daily home visual training task.

Group II: Normative Comparator: Control SubjectsActive Control1 Intervention

Healthy control subjects will be recruited to collect normative data by which to compare test results from CB subjects. No home training will be asked.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Training in the Blind Field

2003

N/A

~280

0 / 12Eligibility criteria met